Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
Hanseeuw B, Betensky R, Jacobs H, Schultz A, Sepulcre J, Becker J, Cosio D, Farrell M, Quiroz Y, Mormino E, Buckley R, Papp K, Amariglio R, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall G, Chhatwal J, Rentz D, Sperling R, Johnson K. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology 2019, 76: 915-924. PMID: 31157827, PMCID: PMC6547132, DOI: 10.1001/jamaneurol.2019.1424.Peer-Reviewed Original ResearchMild cognitive impairmentOlder adultsChoice of outcome measuresPreclinical Alzheimer Cognitive CompositeCognitive impairmentAssociated with cognitive changesProspective cohort studyClinically normal participantsCognitive changesAssociated with subsequent changesMeasure cognitive changeHarvard Aging Brain StudyMeasured 7 yearsPreclinical Alzheimer's diseaseAging Brain StudyPittsburgh compound B PETAlzheimer's diseaseNormal older adultsPrevention trialsOutcome measuresSerial mediation modelCohort studyInclusion criteriaCompound B PETCognitive composite
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply